TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12668800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Between-occasion measurements
Number of subjects: 85
Study: 11196760

Group type: EXPERIMENTAL
Intervention: Ferric polymaltose (6 mg/kg/d)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Ferrous sulphate (6 mg/kg/d)
Number of subjects: 123
Study: 8653568

Group type: EXPERIMENTAL
Intervention: Polyurethane graft (PUR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dacron graft
Number of subjects: 20
Study: 1385971

Group type: EXPERIMENTAL
Intervention: Frusemide (40 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (0.5 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 10
Study: 6147051

Group type: EXPERIMENTAL
Intervention: Oxmetidine 200 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oxmetidine 400 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oxmetidine 800 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oxmetidine (all doses)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oxmetidine (800 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oxmetidine (highest dose)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oxmetidine (400 mg)
Number of subjects: 6
Study: 30614901

Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 131
Study: 29266965

Group type: EXPERIMENTAL
Intervention: Intensified-dose ICS/LABA
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 26440923

Group type: EXPERIMENTAL
Intervention: 0.5 μg vitamin D3 per day
Number of subjects: 90
Study: 26591679

Group type: EXPERIMENTAL
Intervention: Acupuncture-Medicine
Number of subjects: 126

Group type: COMPARATOR
Intervention: Medicine
Number of subjects: 126
Study: 23180950

Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control monitoring
Number of subjects: 59
Study: 20136801

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 124
Study: 18383869

Group type: EXPERIMENTAL
Intervention: Confocal endomicroscopy
Number of subjects: 0
Study: 15793094

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 11
Study: 11934246

Group type: EXPERIMENTAL
Intervention: Loaded hypokinetic subjects (LHKS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Unloaded hypokinetic subjects (UHKS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Loaded ambulatory control subjects (LACS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unloaded ambulatory control subjects (UACS)
Number of subjects: 40
Study: 10356137

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) 0.25 mg/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM)
Number of subjects: 20
Study: 8619455

Group type: EXPERIMENTAL
Intervention: Meglumine ioxitalamate (100 mL via nasogastric tube)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard conservative treatment without contrast material
Number of subjects: 50
Study: 1923175

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 71

Group type: COMPARATOR
Intervention: Clindamycin plus gentamicin
Number of subjects: 71
Study: 6094458

Group type: COMPARATOR
Intervention: Cefotaxime 0.5 g single dose
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Cefotaxime 0.5 g twice a day for 10 days
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Cefotaxime 1 g twice or three times a day for 10 days
Number of subjects: 281
Study: 31800488

Group type: EXPERIMENTAL
Intervention: 0.6 mg scopolamine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 mg mecamylamine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 29651664

Group type: EXPERIMENTAL
Intervention: Chemotherapy only
Number of subjects: 1740

Group type: EXPERIMENTAL
Intervention: Surgery only
Number of subjects: 1740

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy + surgery
Number of subjects: 1740

Group type: EXPERIMENTAL
Intervention: Surgery + adjuvant chemotherapy
Number of subjects: 1740

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 1740

Group type: EXPERIMENTAL
Intervention: Any chemotherapy with surgery
Number of subjects: 1740
Study: 25630713

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 75
Study: 24269858

Group type: EXPERIMENTAL
Intervention: rhBMP-2
Number of subjects: 144

Group type: COMPARATOR
Intervention: autograft/allograft
Number of subjects: 144
Study: 19380753

Group type: EXPERIMENTAL
Intervention: Daily enteral supplementation with zinc, selenium, and glutamine plus parenteral metoclopramide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enteral supplementation with whey protein
Number of subjects: 0
Study: 15067161

Group type: EXPERIMENTAL
Intervention: Contingent management of disability benefits
Number of subjects: 41

Group type: COMPARATOR
Intervention: Noncontingent management of disability benefits
Number of subjects: 41
Study: 11423056

Group type: COMPARATOR
Intervention: 5-mg warfarin group
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: 2.5-mg warfarin group
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 197
Study: 9421775

Group type: EXPERIMENTAL
Intervention: Single dose of cefuroxime (3 g or 1.5 g)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single dose of vancomycin (1.5 g)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: One-day course of cefuroxime
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Additional dose during cardiopulmonary bypass of cefuroxime
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single dose of cefuroxime
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single dose of vancomycin
Number of subjects: 60
Study: 8335738

Group type: EXPERIMENTAL
Intervention: Topical fluocinolone acetonide ointment (0.025%) diluted by area of application
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Topical fluocinolone acetonide ointment (0.025%) diluted by volume (1:1 and 1:3)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: In vitro method measuring fluocinolone release from diluted ointments
Number of subjects: 20
Study: 3117998

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg/d lipid for 5 days (group 1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg/d increased to 2.0 g/kg/d over 5 days (group 2)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lipid infusion at 0.5 to 2.0 g/kg/d
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lipid infusion
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Enzymatically determined triglycerides
Number of subjects: 21
Study: 30591165

Group type: EXPERIMENTAL
Intervention: Incremental advancement (IA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Maximum advancement (MA)
Number of subjects: 42
Study: 29936091

Group type: EXPERIMENTAL
Intervention: Onnikka system (web-based HBCSS)
Number of subjects: 43
Study: 26785406

Group type: EXPERIMENTAL
Intervention: HeLP‐her self‐management lifestyle intervention (1 group session, monthly SMS text messages, 1 phone coaching session, program manual)
Number of subjects: 649

Group type: COMPARATOR
Intervention: General women's health education session (control group)
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: HeLP‐her self‐management lifestyle intervention
Number of subjects: 649
Study: 25197804

Group type: EXPERIMENTAL
Intervention: Intravenous acetazolamide (10 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral indomethacin (100 mg)
Number of subjects: 12
Study: 22252827

Group type: EXPERIMENTAL
Intervention: Rifampin 450 mg daily
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg daily
Number of subjects: 1
Study: 19210274

Group type: EXPERIMENTAL
Intervention: Interdialytic weight gain (IDWG)
Number of subjects: 97
Study: 17179509

Group type: EXPERIMENTAL
Intervention: Malnutrition (SGA categorized)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Normal nutritional status (SGA categorized)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Malnutrition (SGA)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nutritional Risk Index (NRI)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Serum albumin level
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Calorie intake
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: SGA (multivariate analysis)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Normal nutrition
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Malnutrition
Number of subjects: 56
Study: 15173147

Group type: EXPERIMENTAL
Intervention: Progresa intervention group (n = 373)
Number of subjects: 650

Group type: COMPARATOR
Intervention: Crossover intervention group (n = 277)
Number of subjects: 650
Study: 11228084

Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg twice daily
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 9929322

Group type: EXPERIMENTAL
Intervention: Automated Term Composition (ATC) algorithm
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Non-compositional mappings (without ATC)
Number of subjects: 1000
Study: 7886417

Group type: EXPERIMENTAL
Intervention: Intraurethral capsaicin (10(‐5) M)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intracavernosal papaverine hydrochloride (8 mg) plus intraurethral capsaicin (10(‐5) M)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intracavernosal papaverine hydrochloride (8 mg) plus intraurethral saline infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intraurethral saline solution
Number of subjects: 20
Study: 3279748

Group type: EXPERIMENTAL
Intervention: Folic acid (10 mg/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ascorbate (Control)
Number of subjects: 50
Study: 30025466

Group type: EXPERIMENTAL
Intervention: Survival processing effect in isolated condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recognition rates for isolated condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived isolation in grasslands scenarios
Number of subjects: 0
Study: 27986972

Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU weekly for 12 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 25651782

Group type: EXPERIMENTAL
Intervention: Tofacitinib 15 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib (0.5 mg, 3 mg, 10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopic remission (Mayo endoscopy score of 0)
Number of subjects: 0
Study: 23991625

Group type: EXPERIMENTAL
Intervention: Preventive PCI
Number of subjects: 465

Group type: COMPARATOR
Intervention: No preventive PCI (infarct-artery-only PCI)
Number of subjects: 465
Study: 21903531

Group type: EXPERIMENTAL
Intervention: Cetylpyridinium chloride in combination with sodium fluoride
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate and sodium fluoride
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (fluoride toothpaste and rinsing with water)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sodium monofluorophosphate
Number of subjects: 12
Study: 19036672

Group type: EXPERIMENTAL
Intervention: Tigecycline (TGC)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Levofloxacin (LEV)
Number of subjects: 358
Study: 16310895

Group type: EXPERIMENTAL
Intervention: Heparin 1500 units
Number of subjects: 110

Group type: COMPARATOR
Intervention: Hydrocortisone 15 mg
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Combination of Heparin and Hydrocortisone
Number of subjects: 110
Study: 14600553

Group type: EXPERIMENTAL
Intervention: INT (maintained training intensity but reduced duration)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: DUR (maintained training duration but reduced exercise intensity)
Number of subjects: 22

Group type: COMPARATOR
Intervention: All groups combined
Number of subjects: 22

Group type: COMPARATOR
Intervention: CON (continued weekly training)
Number of subjects: 22
Study: 10724078

Group type: EXPERIMENTAL
Intervention: TENS 1 (5 Hz)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: TENS 2 (100 Hz)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: TENS 3 (200 Hz)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: IFT 1 (5 Hz)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: IFT 2 (100 Hz)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: IFT 3 (200 Hz)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study: 9366278

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 312

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 312
Study: 1539506

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (streptokinase)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (rt-PA)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy preceded by acetylsalicylic acid
Number of subjects: 50

Group type: COMPARATOR
Intervention: No thrombolytic therapy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Reperfused patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: Occluded patients
Number of subjects: 50
Study: 3894707

Group type: EXPERIMENTAL
Intervention: Single 2-g dose of metronidazole
Number of subjects: 82

Group type: COMPARATOR
Intervention: Seven-day course of 500 mg metronidazole given twice daily
Number of subjects: 82
Study: 31323378

Group type: EXPERIMENTAL
Intervention: High baseline anxiety or depression
Number of subjects: 1159

Group type: EXPERIMENTAL
Intervention: Extra-GI symptoms
Number of subjects: 1159

Group type: COMPARATOR
Intervention: Anxiety or depression
Number of subjects: 1159
Study: 30015668

Group type: EXPERIMENTAL
Intervention: Lactoferrin
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 26768925

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 90

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 90
Study: 25302763

Group type: EXPERIMENTAL
Intervention: MBCT‐SH
Number of subjects: 80

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 80
Study: 22918524

Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Speed of processing training
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 82
Study: 20194027

Group type: EXPERIMENTAL
Intervention: Suction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-suction
Number of subjects: 0
Study: 18084150

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mitral valve repair or replacement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery of left ventricular shape and volume restoration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ongoing prospective randomized studies (Surgical Treatment for Ischemic Heart Disease trial, Heart Failure Revascularization trial, PET and Recovery Following Revascularization-2 trial)
Number of subjects: 0
Study: 16045667

Group type: EXPERIMENTAL
Intervention: Infraclavicular block (single injection)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Axillary block (multiple injections)
Number of subjects: 80
Study: 12225436

Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 135

Group type: COMPARATOR
Intervention: Anti-thymocyte globulin (ATGAM)
Number of subjects: 135
Study: 10223773

Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg once a day for 5 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7872274

Group type: EXPERIMENTAL
Intervention: Olsalazine (1 g daily)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Sulphasalazine (2 g daily)
Number of subjects: 322
Study: 2152843

Group type: EXPERIMENTAL
Intervention: Post-Hospital Support Program
Number of subjects: 191

Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 191
Study: 680588

Group type: EXPERIMENTAL
Intervention: Unrestricted sodium intake
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Partial removal of ascites (limitation of diuresis)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Complete diuresis
Number of subjects: 201

Group type: COMPARATOR
Intervention: Low sodium diet
Number of subjects: 201
Study: 31733140

Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg once daily)
Number of subjects: 4745
Study: 28081288

Group type: EXPERIMENTAL
Intervention: Short implants (6 mm)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Long implants (11‐15 mm)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Long implants (11‐15 mm) with sinus grafting
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Short implants (6 mm) with sinus grafting
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 101
Study: 25596939

Group type: EXPERIMENTAL
Intervention: Evicel™ (biologic glue)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Over suture of the stapler line
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control
Number of subjects: 165
Study: 23414585

Group type: EXPERIMENTAL
Intervention: Ganitumab (12 mg/kg bodyweight) + Fulvestrant (500 mg on day 1, then 250 mg on days 15, 29, and every 28 days)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Ganitumab (12 mg/kg bodyweight) + Exemestane (25 mg once daily)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo + Fulvestrant (500 mg on day 1, then 250 mg on days 15, 29, and every 28 days)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo + Exemestane (25 mg once daily)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Ganitumab (12 mg/kg bodyweight)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 19858112

Group type: EXPERIMENTAL
Intervention: Correct feedback (COR)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Non-contingent feedback (FAL)
Number of subjects: 5
Study: 19118617

Group type: EXPERIMENTAL
Intervention: Shi-Bi-Lin (SBL) capsules
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 16500713

Group type: EXPERIMENTAL
Intervention: Amphetamine (30 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 14693608

Group type: EXPERIMENTAL
Intervention: Electric needle acupuncture over 15 min at analgesic points of the leg (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham treatment (n = 8)
Number of subjects: 16
Study: 11020090

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation-based stress reduction program (weekly meditation group lasting 1.5 hours for 7 weeks plus home meditation practice)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 90
Study: 9362436

Group type: EXPERIMENTAL
Intervention: Gallium nitrate (40 mg administered as a subcutaneous injection once daily for 2 weeks, followed by 2 weeks off treatment, recycled monthly)
Number of subjects: 0
Study: 7510194

Group type: EXPERIMENTAL
Intervention: G-CSF administration
Number of subjects: 0
Study: 3511159

Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 25

Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 25
Study: 3174261

Group type: EXPERIMENTAL
Intervention: Monotonous stimulation (sequence of tones)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No tones (quiet room)
Number of subjects: 60
Study: 31506918

Group type: EXPERIMENTAL
Intervention: Needle tip tracking
Number of subjects: 25

Group type: COMPARATOR
Intervention: No needle tip tracking (control)
Number of subjects: 25
Study: 30991829

Group type: EXPERIMENTAL
Intervention: Fine-Needle Aspiration (FNA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 24
Study: 27619354

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including education, guideline development, elimination of recurring laboratory orders, unbundling of laboratory panels, redesign of the daily progress note.
Number of subjects: 5392

Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 5392
Study: 26276164

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) - 150 ml ropivacaine 0.2 % with epinephrine intra‐operatively
Number of subjects: 61

Group type: COMPARATOR
Intervention: Interscalene brachial plexus catheter (ISC) - ropivacaine 0.75 %, 7 ml bolus followed by 48‐h 5 ml/h infusion
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Interscalene brachial plexus catheter (ISC)
Number of subjects: 61
Study: 23505176

Group type: EXPERIMENTAL
Intervention: Three 500 calorie liquid meals every 4 hours
Number of subjects: 8

Group type: COMPARATOR
Intervention: Six 250 calorie liquid meals every 2 hours
Number of subjects: 8
Study: 21143256

Group type: EXPERIMENTAL
Intervention: Predefined pharmacist intervention focusing on correct medication use, medication adherence, and healthy lifestyle promotion
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Predefined pharmacist intervention with sustained pharmacotherapy changes
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control group receiving usual pharmacist care
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Intervention group receiving pharmacist intervention
Number of subjects: 288
Study: 19941542

Group type: EXPERIMENTAL
Intervention: Interactive education programme for 1 hour and educational booklet
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (received the same intervention separately after post-test)
Number of subjects: 90
Study: 17009533

Group type: EXPERIMENTAL
Intervention: Prostate + levofloxacin (first 4 weeks), Prostate only (next 4 weeks)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo + levofloxacin (first 4 weeks), Placebo only (next 4 weeks)
Number of subjects: 160